<DOC>
	<DOCNO>NCT02281370</DOCNO>
	<brief_summary>A drug-drug interaction study eltrombopag cyclosporine conduct support use drug together subject , severe aplastic anemia immune thrombocytopenia purpura . The primary objective study evaluate effect cyclosporine pharmacokinetics eltrombopag . This Phase I , open-label , randomize , three-period cross-over study healthy adult subject . The study consist screen visit three treatment period . All subject randomize receive one three treatment treatment period separate washout period 3-10 day . The total duration subject 's participation study screen final discharge approximately 6 week ( assume 3 day washout treatment period ) . Approximately 39 healthy subject enrol goal complete least 10 subject per sequence ( total 30 ) .</brief_summary>
	<brief_title>Drug-drug Interaction Study Eltrombopag Cyclosporine Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Between 18 64 year age inclusive . Healthy subject . Body weight &gt; =60 kilogram ( kg ) men woman body mass index ( BMI ) within range 24.732.0 kg/meter square ( m^2 ) inclusive . Male : Men female partner childbearing potential must either prior vasectomy agree use effective contraception study . Female nonchild bear potential . Female childbearing potential negative serum urine pregnancy test willing practice acceptable method birth control study . Capable give sign informed consent include compliance requirement restriction list consent form protocol . Alanine aminotransferase ( ALT ) bilirubin &gt; 1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . QT interval correct ( QTc ) &gt; 450 millisecond ( msec ) : The QTc QT interval correct heart rate accord Bazett 's formula ( QTcB ) , Fridericia 's formula ( QTcF ) , and/or another method , machineread manually overread . For purpose data analysis , QTcB , QTcF , another QT correction formula , composite available value QTc use . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St. John 's Wort ) within 7 day . Requiring use oral injectable strong Cytochrome P3A4 ( CYP3A4 ) Breast cancer resistance protein ( BRCP ) inhibitor use CYP3A4 BCRP inhibitors/inducers within 14 day prior dose . History regular alcohol consumption within 1 month study . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 30 day prior screen . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Platelet count creatinine level exceed upper limit normal range . Presence hepatitis B surface antigen ( HBsAg ) presence hepatitis B core antibody ( HBcAb ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment A positive prestudy drug/alcohol screen . A positive test human immune virus ( HIV ) antibody . Where participation study would result donation blood blood product excess 500 mL within 56day period . The subject participate clinical trial receive investigational product within 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>eltrombopag</keyword>
	<keyword>cyclosporine</keyword>
	<keyword>drug-drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>SB-497115</keyword>
</DOC>